The Latest Cardiac and Vascular News
Clinical research study at leading U.S. hospital will further validate the efficacy of advanced, AI-powered magnetocardiography for transformative cardiac diagnostics PALO ALTO, Calif., Aug. 8, 2024 /PRNewswire/ — SandboxAQ today announced a technology collaboration with Mayo Clinic to…
Eko Health outfits LSU Athletic Sports Medicine team with CORE 500 digital stethoscopes and AI algorithms for the enhanced detection of cardiac conditions during athlete physical exams BATON ROUGE, La. & SAN FRANCISCO, Aug. 8, 2024 /PRNewswire/ — Eko Health, a pioneer in applying…
ATLANTA, Aug. 5, 2024 /PRNewswire/ — Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences. Artivion’s management team will present at the upcoming Canaccord…
FINEARTS-HF met its primary endpoint,1 achieving a statistically significant reduction of the composite of cardiovascular death and total (first and recurrent) heart failure (HF) events, defined as hospitalizations for HF or urgent HF visits 2 KERENDIA is the first non-steroidal, selective mineralocorticoid receptor antagonist (MRA) to meet a primary cardiovascular endpoint in […]
July 30, 2024 01:00 AM Eastern Daylight Time LUXEMBOURG & AACHEN, Germany–(BUSINESS WIRE)–The European Investment Bank (EIB) is providing €20 million in venture-debt financing to German medical-technology company Protembis to develop a next-generation device for protecting the brains of patients who undergo certain heart treatments. “This agreement demonstrates our commitment […]
Tirzepatide reduced the risk of heart failure outcomes – heart failure urgent visit or hospitalization, oral diuretic intensification or cardiovascular death – by 38% compared to placebo Tirzepatide significantly improved heart failure symptoms and physical limitations Tirzepatide led to…
MINNEAPOLIS, July 31, 2024 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, today announced that the management team will present at the Canaccord Genuity 44th Annual Growth Conference on Wednesday, August 14, 2024. The Company is scheduled to present at 12:30 PM Eastern Time the same day via webcast.A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com.About CVRx, Inc.CVRx is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.Investor Contact:Mark Klausner or Mike VallieICR Westwicke443-213-0501ir@cvrx.comMedia Contact:Laura O’NeillFinn Partners402-499-8203laura.oneill@finnpartners.com
NEW YORK, July 31, 2024 /PRNewswire/ — An artificial intelligence program created explanations of heart test results that were in most cases accurate, relevant, and easy to understand by patients, a new study finds. The study addressed the echocardiogram (echo), which uses sound waves to…
CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a leader in AI-powered precision cardiovascular medicine, today announced the launch of its redesigned website at CDIO.AI. This new site emphasizes the Company’s AI-first approach and innovative scalable solutions for the prevention, detection and management of cardiovascular disease, which is the leading cause of death […]
HOPEWELL, N.J. , July 29, 2024 /PRNewswire/ — The aorta is the largest blood vessel in the body, and diseases or injury to the aorta can be life threatening. Offering the latest advance in minimally invasive surgery to restore function to damaged aortas, vascular surgeons at Capital…
